Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Qiao-Li Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4152-7821; OpenAlex author ID A5066211017, A5069560221. Sources: OpenAlex.

Their work

Papers
15 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2022: 3 papers · 2023: 5 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 15

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Risk of Pancreatic Cancer Associated With Precursor Lesions in Individuals and First-Degree Relatives: A Nationwide Cohort Study. Last author DOI 10.1016/j.cgh.2026.06.009↗
  3. Reply to the Letter to the Editor regarding “Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early … Co-author DOI 10.1016/j.pan.2025.04.017↗
  4. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. First author DOI 10.1136/gutjnl-2023-331074↗
  6. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Co-author DOI 10.3389/fimmu.2024.1210859↗
  7. [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. Co-author DOI 10.3760/cma.j.cn112152-20231223-00383↗
  8. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. First author DOI 10.1038/s41467-023-38088-2↗
  9. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  10. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/21645515.2023.2178791↗
  11. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. First author DOI 10.1158/1055-9965.epi-23-0505↗
  12. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. First author DOI 10.14309/ctg.0000000000000573↗
  13. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  14. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Co-author DOI 10.1080/21645515.2022.2143154↗
  15. Temporal Association of Total Serum Cholesterol and Pancreatic Cancer Incidence. Co-author DOI 10.3390/nu14224938↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 9 shared papers, 2022–2026 · strength 1.49
  2. Chen Yuan · 8 shared papers, 2022–2026 · strength 1.33
  3. Ana Babić · 6 shared papers, 2022–2024 · strength 0.79
  4. Kimmie Ng · 6 shared papers, 2022–2024 · strength 0.79
  5. Jonathan Andrew Nowak · 5 shared papers, 2023–2026 · strength 0.76
  6. Edward L. Giovannucci · 5 shared papers, 2022–2023 · strength 0.69
  7. Xin Qiu · 4 shared papers, 2022–2024 · strength 0.67
  8. Alice A. Lee · 5 shared papers, 2022–2023 · strength 0.66
  9. Peter Kraft · 4 shared papers, 2022–2023 · strength 0.53
  10. Changchang Lu · 3 shared papers, 2022–2024 · strength 0.52
  11. Juan Du · 3 shared papers, 2022–2024 · strength 0.52
  12. Fan Tong · 3 shared papers, 2022–2024 · strength 0.52
  13. Baorui Liu · 3 shared papers, 2022–2024 · strength 0.52
  14. Michael Hayden Rosenthal · 3 shared papers, 2023–2026 · strength 0.49
  15. Douglas W. Mahoney · 2 shared papers, 2024–2025 · strength 0.43
  16. Lynette M. Smith · 2 shared papers, 2024–2025 · strength 0.43
  17. Ann L. Oberg · 2 shared papers, 2024–2025 · strength 0.43
  18. Randall E. Brand · 2 shared papers, 2024–2025 · strength 0.43
  19. Michael Goggins · 2 shared papers, 2024–2025 · strength 0.43
  20. Gregory A. Coté · 2 shared papers, 2024–2025 · strength 0.43
  21. Kimberly J. Perez · 3 shared papers, 2022–2023 · strength 0.39
  22. Huizi Sha · 2 shared papers, 2024 · strength 0.36
  23. Jacob Edward Till · 2 shared papers, 2024–2026 · strength 0.34
  24. Erica L. Carpenter · 2 shared papers, 2024–2026 · strength 0.34
  25. Mark H. O’Hara · 2 shared papers, 2024–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.